Voxelotor is a haemoglobin oxygen-affinity modulator approved by the FDA in 2019 for the treatment of sickle cell disease. About 90% of the global sickle cell population lives in LMICs. Voxelotor has a different mode of action from that of conventional standard of care therapies, which makes it relevant as additional treatment or in case of intolerance.